deucravacitinib
Sponsor Bristol Myers Squibb CO · listed as BMY
deucravacitinib is a drug asset sponsored by Bristol Myers Squibb CO, listed as BMY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 19, 2026 (day precision, medium confidence), tied to trial NCT05617677. That trial is in Phase 3 and currently active not recruiting, studying Systemic Lupus Erythematosus. It appears across 13 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for deucravacitinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04908202 | Phase 3 | Active, not recruiting | 2024-09-05 | Experimental | Bristol-Myers Squibb | Psoriatic Arthritis |
| NCT06143878 | Phase 3 | Active, not recruiting | 2024-09-17 | Active comparator | Janssen Research & Development, LLC | Plaque Psoriasis |
| NCT04908189 | Phase 3 | Active, not recruiting | 2024-11-07 | Experimental | Bristol-Myers Squibb | Psoriatic Arthritis |
| NCT06220604 | Phase 3 | Active, not recruiting | 2024-11-15 | Active comparator | Janssen Research & Development, LLC | Plaque Psoriasis |
| NCT05617677 catalyst | Phase 3 | Active, not recruiting | 2026-10-19 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus |
| NCT05620407 | Phase 3 | Active, not recruiting | 2026-10-19 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus |
| NCT07326813 | Phase 3 | Recruiting | 2027-07-12 | Active comparator | InventisBio Co., Ltd | Plaque Psoriasis |
| NCT07724366 | Phase 3 | Recruiting | 2027-09 | Active comparator | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Psoriasis |
| NCT04772079 | Phase 3 | Recruiting | 2029-01-01 | Experimental | Bristol-Myers Squibb | Plaque Psoriasis |
| NCT06979453 | Phase 3 | Recruiting | 2029-10-12 | Active comparator | Bristol-Myers Squibb | Plaque Psoriasis |
| NCT06869551 | Phase 3 | Recruiting | 2030-03-06 | Experimental | Bristol-Myers Squibb | Juvenile Psoriatic Arthritis |
| NCT07791199 | Phase 3 | Not yet recruiting | 2030-10-31 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis |
| NCT07116967 | Phase 3 | Recruiting | 2031-01-16 | Experimental | Bristol-Myers Squibb | Plaque Psoriasis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More BMY catalysts